A critical review of the cannabinoid receptor as a drug target for obesity management
- 23 December 2008
- journal article
- review article
- Published by Wiley in Obesity Reviews
- Vol. 10 (1) , 58-67
Abstract
Summary: The discovery of cannabinoids, with the well‐known stimulatory effect of Cannabis sativa on appetite, has offered a new drug target for obesity treatment. Cannabinoids act on two different receptors: CB1 receptors which are sited in the brain and many peripheral tissues, and CB2 receptors which are primarily found in immune system cells. Cannabinoid receptor antagonists act centrally by blocking CB1 receptors, thereby reducing food intake. Moreover, they probably also act peripherally by increasing thermogenesis and therefore energy expenditure, as has been suggested by animal experiments. Despite these promising mechanisms of action, recent clinical studies examining the effect of the two CB1 receptor antagonists rimonabant and taranabant showed that the attained weight loss did not exceed that attained with other currently approved anti‐obesity medications. Moreover, potentially severe psychiatric adverse effects limit their clinical use. As several new CB1 receptor antagonists are presently undergoing development, it remains to be elucidated to what extent they differ in terms of efficacy and safety. This review primarily discusses how close cannabinoid receptor antagonists are to the ideal anti‐obesity drug, with respect to their mechanisms of action, clinical effectiveness and safety.Keywords
This publication has 76 references indexed in Scilit:
- Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic RatsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioningBritish Journal of Pharmacology, 2008
- Cannabinoid CB2receptors: a therapeutic target for the treatment of inflammatory and neuropathic painBritish Journal of Pharmacology, 2008
- Cannabinoid receptors in acute and chronic complications of atherosclerosisBritish Journal of Pharmacology, 2008
- Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1JNCI: Journal of the National Cancer Institute, 2008
- Long term pharmacotherapy for obesity and overweight: updated meta-analysisBMJ, 2007
- Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary arteryJournal Of Hypertension, 2007
- Modulation of the endocannabinoid system: Therapeutic potential against cocaine dependencePharmacological Research, 2007
- Current and Future Prevalence of Obesity and Severe Obesity in the United StatesForum for Health Economics and Policy, 2007
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006